Savolitinib in Treating Patients With Recurrent or Refractory Primary CNS Tumors

Summary

This phase I trial studies the side effects and best dose of savolitinib in treating patients with primary central nervous system (CNS) tumors that have come back (recurrent) or does not respond to treatment (refractory). Savolitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Timeline

Start

2018-11-27

Primary completion

2025-04-14

Completion

2026-09-12

Drugs

Indications